Pfizer’s ABRYSVO became the first and only RSV vaccine approved for use in adults under 50, offering the most extensive RSV vaccine coverage for adults. The label expansion announced on 22 October 2024 includes younger adults considered at higher risk for RSV-related lower respiratory tract disease (LRTD).
ABRYSVO (RSVpreF) is a sterile solution for intramuscular injection. The vaccine is supplied as a vial of lyophilized antigen component that is reconstituted at the time of use with a sterile water diluent component. The antigen component contains recombinant RSV preF A and RSV preF B.
In May 2023, the FDA approved ABRYSVO to prevent LRTD caused by...
